References
- Maartens G, Wilkinson RJ. TB. Lancet370(9604), 2030–2043 (2007).
- WHO. Global TB control: surveillance, planning, and financing. WHO Report 2007. Geneva, Switzerland (2007).
- Chapman HT. On the use of cod-liver oil in diseases of the bones and joints, in consumption and in other maladies attended by great emaciation. Phamaceutical Transactions1–16 (1849).
- Charpy J. Quelques traitments vitaminés ou par substances fonctionelles en dermatologie. Bull. Méd.24, 505 (1950).
- Martineau AR, Honecker FU, Wilkinson RJ, Griffiths CJ. Vitamin D in the treatment of pulmonary TB. J. Steroid Biochem. Mol. Biol.103, 793–798 (2007).
- Davies PD. A possible link between vitamin D deficiency and impaired host defence to Mycobacterium tuberculosis. Tubercle66(4), 31–36 (1985).
- Wilkinson RJ, Llewelyn M, Toossi Z et al. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on TB among Gujarati Asians in west London: a case-control study. Lancet355(9204), 618–621 (2000).
- Martineau AR, Wilkinson RJ, Wilkinson KA et al. A single dose of vitamin D enhances immunity to mycobacteria. Am. J. Respir. Crit. Care Med.176(2), 8–13 (2000).
- Crowle AJ, Ross EJ, May MH. Inhibition by 1,25(OH)2-vitamin D3 of the multiplication of virulent tubercle bacilli in cultured human macrophages. Infect. Immun.55(12), 2945–2950 (1987).
- Norman AW, Mizwicki MT, Norman DP. Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat. Rev. Drug Discov.3(1), 27–41 (2004).
- Martineau AR, Wilkinson KA, Newton SM et al. IFN-γ- and TNF-independent vitamin D-inducible human suppression of mycobacteria: the role of cathelicidin LL-37. J. Immunol.178(11), 7190–7198 (2007).
- Wang TT, Nestel FP, Bourdeau V et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J. Immunol.173(5), 2909–2912 (2004).
- Liu PT, Stenger S, Li H et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science311(5768), 1770–1773 (2006).
- Martineau AR, Newton SM, Wilkinson KA et al. Neutrophil-mediated innate immune resistance to mycobacteria. J. Clin. Invest.117(7), 1988–1994 (2007).
- Liu PT, Stenger S, Tang DH, Modlin RL. Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium TB is dependent on the induction of cathelicidin. J. Immunol.179(4), 260–263 (2007).
- Vieth R, McCarten K, Norwich KH. Role of 25-hydroxyvitamin D3 dose in determining rat 1,25-dihydroxyvitamin D3 production. Am. J. Physiol.258(5 Pt 1), E780–E789 (1990).
- Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations and safety. Am. J. Clin. Nutr.69, 842–856 (1999).
- Morcos MM, Gabr AA, Samuel S et al. Vitamin D administration to tuberculous children and its value. Boll. Chim. Farm.137(5)1, 57–64 (1998).
- Nursyam EW, Amin Z, Rumende CM. The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion. Acta Med. Indones.38(1), 3–5 (2006).
- Mitchison DA. The diagnosis and therapy of TB during the past 100 years. Am. J. Respir. Crit. Care Med.171(7), 699–706 (2005).
- Mitchison DA. Assessment of new sterilizing drugs for treating pulmonary TB by culture at 2 months. Am. Rev. Respir. Dis.147(4), 162–163 (1993).
- Feeny PJ. Calciferol in TB. Lancet438–443 (1947).
- Kimball SM, Ursell MR, O’Connor P, Vieth R. Safety of vitamin D3 in adults with multiple sclerosis. Am. J. Clin. Nutr.86(3), 645–651 (2007).
- Narang NK, Gupta RC, Jain MK. Role of vitamin D in pulmonary TB. J. Assoc. Physicians India32(2), 185–188 (1984).
- Dupont WD, Plummer WD. PS power and sample size program available for free on the Internet. Controlled Clin. Trials18, 274 (1997).
- Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporos. Int.16(7), 713–716 (2005).
Website
- Martineau AR. Protocol 06PRT/7641: Trial of adjunctive vitamin D in TB treatment (AdjuVIT) (NCT00419068). www.thelancet.com/journals/lancet/misc/protocol/06PRT-7641.